An update on, and genetics of refractory adenomas of childhood.
Childhood
Genetics
Pituitary adenomas
Therapy
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
accepted:
16
05
2023
medline:
12
7
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
Pituitary adenomas in childhood tend to be more frequently due to germline genetic changes and are often diagnosed at late stages due to delayed recognition by pediatricians and other caretakers who are not familiar with this rare disease in childhood. As a result, often, pediatric pituitary adenomas are aggressive or remain refractory to treatment. In this review, we discuss germline genetic defects that account for the most common pediatric pituitary adenomas that are refractory to treatment. We also discuss some somatic genetic events, such as chromosomal copy number changes that characterize some of the most aggressive pituitary adenomas in childhood that end up being refractory to treatment.
Identifiants
pubmed: 37318708
doi: 10.1007/s11102-023-01327-2
pii: 10.1007/s11102-023-01327-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
281-287Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Raappana A, Koivukangas J, Ebeling T, Pirila T (2010) Incidence of pituitary adenomas in Northern Finland in 1992–2007. J Clin Endocrinol Metab 95:4268–4275. https://doi.org/10.1210/jc.2010-0537
doi: 10.1210/jc.2010-0537
pubmed: 20534753
Ezzat S et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613–619. https://doi.org/10.1002/cncr.20412
doi: 10.1002/cncr.20412
pubmed: 15274075
Agustsson TT et al (2015) The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study. Eur J Endocrinol 173:655–664. https://doi.org/10.1530/EJE-15-0189
doi: 10.1530/EJE-15-0189
pubmed: 26423473
Daly AF et al (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769–4775. https://doi.org/10.1210/jc.2006-1668
doi: 10.1210/jc.2006-1668
pubmed: 16968795
Keil MF, Stratakis CA (2008) Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev Neurother 8:563–574. https://doi.org/10.1586/14737175.8.4.563
doi: 10.1586/14737175.8.4.563
pubmed: 18416659
pmcid: 2743125
Yoo F, Kuan EC, Heaney AP, Bergsneider M, Wang MB (2018) Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review. Pituitary 21:290–301. https://doi.org/10.1007/s11102-018-0872-8
doi: 10.1007/s11102-018-0872-8
pubmed: 29404894
WHO (2017) Classifcation of tumours of endocrine organs. IARC Publications, Lyon
Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101:87–104. https://doi.org/10.1159/000371806
doi: 10.1159/000371806
pubmed: 25571935
Raverot G et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1–G24. https://doi.org/10.1530/EJE-17-0796
doi: 10.1530/EJE-17-0796
pubmed: 29046323
Trouillas J et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126:123–135. https://doi.org/10.1007/s00401-013-1084-y
doi: 10.1007/s00401-013-1084-y
pubmed: 23400299
McCormack A et al (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a european Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178:265–276. https://doi.org/10.1530/EJE-17-0933
doi: 10.1530/EJE-17-0933
pubmed: 29330228
Trouillas J et al (2018) Aggressive pituitary tumours and carcinomas: two sides of the same coin? Eur J Endocrinol 178:C7–C9. https://doi.org/10.1530/EJE-18-0250
doi: 10.1530/EJE-18-0250
pubmed: 29588294
Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170:R213–227. https://doi.org/10.1530/EJE-14-0013
doi: 10.1530/EJE-14-0013
pubmed: 24536090
Shrivastava RK, Arginteanu MS, King WA, Post KD (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97:299–306. https://doi.org/10.3171/jns.2002.97.2.0299
doi: 10.3171/jns.2002.97.2.0299
pubmed: 12186457
Delgrange E et al (2014) Giant prolactinomas in women. Eur J Endocrinol 170:31–38. https://doi.org/10.1530/EJE-13-0503
doi: 10.1530/EJE-13-0503
pubmed: 24088550
Jennings JE et al (2009) Aggressive pituitary adenomas occurring in young patients in a large polynesian kindred with a germline R271W mutation in the AIP gene. Eur J Endocrinol 161:799–804. https://doi.org/10.1530/EJE-09-0406
doi: 10.1530/EJE-09-0406
pubmed: 19684062
de Castro LF et al (2018) Beneficial Effects of high doses of Cabergoline in the treatment of Giant Prolactinoma resistant to dopamine agonists: a Case Report with a 21-Year Follow-Up. Horm Res Paediatr 89:63–70. https://doi.org/10.1159/000479511
doi: 10.1159/000479511
pubmed: 28954263
Wu ZB et al (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104:54–61. https://doi.org/10.3171/jns.2006.104.1.54
doi: 10.3171/jns.2006.104.1.54
pubmed: 16509147
Huang HY, Zhai W, Tang H, Hui GZ, Wu ZB (2018) Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas. Endocrine 62:464–469. https://doi.org/10.1007/s12020-018-1702-5
doi: 10.1007/s12020-018-1702-5
pubmed: 30238326
Semple P, Fieggen G, Parkes J, Levitt N (2007) Giant prolactinomas in adolescence: an uncommon cause of blindness. Childs Nerv Syst 23:213–217. https://doi.org/10.1007/s00381-006-0177-5
doi: 10.1007/s00381-006-0177-5
pubmed: 16983572
Salenave S et al (2015) Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab 100:1177–1186. https://doi.org/10.1210/jc.2014-3670
doi: 10.1210/jc.2014-3670
pubmed: 25532043
Cook RJ, Uttley D, Wilkins PR, Archer DJ, Bell BA (1994) Prolactinomas in men masquerading as invasive skull base tumours. Br J Neurosurg 8:51–55
doi: 10.3109/02688699409002393
pubmed: 8011194
Rix M et al (2004) Cushing’s disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol 151:709–715
doi: 10.1530/eje.0.1510709
pubmed: 15588237
Makri A et al (2018) Children with MEN1 gene mutations may present first (and at a young age) with cushing disease. Clin Endocrinol (Oxf) 89:437–443. https://doi.org/10.1111/cen.13796
doi: 10.1111/cen.13796
pubmed: 29927501
Stratakis CA et al (2000) Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 85:4776–4780. https://doi.org/10.1210/jcem.85.12.7064
doi: 10.1210/jcem.85.12.7064
pubmed: 11134142
Melmed S et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273–288. https://doi.org/10.1210/jc.2010-1692
doi: 10.1210/jc.2010-1692
pubmed: 21296991
Yu C, Wu Z, Gong J (2005) Combined treatment of invasive giant prolactinomas. Pituitary 8:61–65. https://doi.org/10.1007/s11102-005-5087-0
doi: 10.1007/s11102-005-5087-0
pubmed: 16411070
Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS (2010) Giant prolactinoma and effectiveness of medical management. Endocr Pract 16:42–46. https://doi.org/10.4158/EP09221.OR
doi: 10.4158/EP09221.OR
pubmed: 19703803
Felker J, Patterson B, Wrubel D, Janss A (2016) Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide. J Pediatr Endocrinol Metab 29:1413–1415. https://doi.org/10.1515/jpem-2016-0159
doi: 10.1515/jpem-2016-0159
pubmed: 27815961
Lasolle H et al (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176:769–777. https://doi.org/10.1530/EJE-16-0979
doi: 10.1530/EJE-16-0979
pubmed: 28432119
Whitelaw BC et al (2012) Temozolomide in the management of dopamine agonist-resistant prolactinomas. Clin Endocrinol (Oxf) 76:877–886. https://doi.org/10.1111/j.1365-2265.2012.04373.x
doi: 10.1111/j.1365-2265.2012.04373.x
pubmed: 22372583
Rostomyan L et al (2015) Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. Endocr Relat Cancer 22:745–757. https://doi.org/10.1530/ERC-15-0320
doi: 10.1530/ERC-15-0320
pubmed: 26187128
pmcid: 6533620
Personnier C et al (2011) Clinical features and treatment of pediatric somatotropinoma: case study of an aggressive tumor due to a new AIP mutation and extensive literature review. Horm Res Paediatr 75:392–402. https://doi.org/10.1159/000327831
doi: 10.1159/000327831
pubmed: 21546764
Stratakis CA et al (2010) The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 78:457–463. https://doi.org/10.1111/j.1399-0004.2010.01406.x
doi: 10.1111/j.1399-0004.2010.01406.x
pubmed: 20507346
pmcid: 3050035
Katznelson L et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. https://doi.org/10.1210/jc.2014-2700
doi: 10.1210/jc.2014-2700
pubmed: 25356808
Gupta P et al (2018) Imatinib inhibits GH Secretion from Somatotropinomas. Front Endocrinol (Lausanne) 9:453. https://doi.org/10.3389/fendo.2018.00453
doi: 10.3389/fendo.2018.00453
pubmed: 30210447
Dutta P et al (2019) Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP MutationPositive child. J Clin Endocrinol Metab 104:3539–3544. https://doi.org/10.1210/jc.2019-00432
doi: 10.1210/jc.2019-00432
pubmed: 31125088
pmcid: 6619489
Nozieres C et al (2011) Sporadic and genetic forms of paediatric somatotropinoma: a retrospective analysis of seven cases and a review of the literature. Orphanet J Rare Dis 6:67. https://doi.org/10.1186/1750-1172-6-67
doi: 10.1186/1750-1172-6-67
pubmed: 22024364
pmcid: 3234180
Crooke AC, Purves HD, Russell DS, Thornton KR (1956) Hyalinization and basophil adenomata in the pituitary gland. Proc R Soc Med 49:1014–1020
pubmed: 13389465
George DH et al (2003) Crooke’s cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol 27:1330–1336
doi: 10.1097/00000478-200310000-00005
pubmed: 14508394
Oldfield EH et al (2015) Crooke’s changes in Cushing’s Syndrome depends on degree of hypercortisolism and individual susceptibility. J Clin Endocrinol Metab 100:3165–3171. https://doi.org/10.1210/JC.2015-2493
doi: 10.1210/JC.2015-2493
pubmed: 26147609
Di Ieva A et al (2015) Crooke’s cell tumors of the pituitary. Neurosurgery 76:616–622. https://doi.org/10.1227/NEU.0000000000000657
doi: 10.1227/NEU.0000000000000657
pubmed: 25635886
Giri D, Roncaroli F, Sinha A, Didi M, Senniappan S (2017) Silent Crooke’s cell corticotroph adenoma of the pituitary gland presenting as delayed puberty. Endocrinol Diabetes Metab Case Rep doi: https://doi.org/10.1530/EDM-16-0153 (2017)
Felix IA, Horvath E, Kovacs K (1981) Massive Crooke’s hyalinization in corticotroph cell adenomas of the human pituitary. A histological, immunocytological, and electron microscopic study of three cases. Acta Neurochir (Wien) 58:235–243. https://doi.org/10.1007/bf01407130
doi: 10.1007/bf01407130
pubmed: 6172012
Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P (2001) Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol 12:329–341
doi: 10.1385/EP:12:3:329
pubmed: 11740054
Kovacs GL et al (2013) ACTH-secreting Crooke cell carcinoma of the pituitary. Eur J Clin Invest 43:20–26. https://doi.org/10.1111/eci.12010
doi: 10.1111/eci.12010
pubmed: 23134557
Jahangiri A et al (2013) A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery 73, 8–17; discussion 17–18, doi: https://doi.org/10.1227/01.neu.0000429858.96652.1e
Nishioka H, Inoshita N, Sano T, Fukuhara N, Yamada S (2012) Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas. Endocr Pathol 23:151–156. https://doi.org/10.1007/s12022-012-9208-9
doi: 10.1007/s12022-012-9208-9
pubmed: 22569896
Cohen-Inbar O et al (2017) Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study. J Neurooncol 135:67–74. https://doi.org/10.1007/s11060-017-2520-y
doi: 10.1007/s11060-017-2520-y
pubmed: 28913674
Zoli M et al (2015) ACTH adenomas transforming their clinical expression: report of 5 cases. Neurosurg Focus 38:E15. https://doi.org/10.3171/2014.11.FOCUS14679
doi: 10.3171/2014.11.FOCUS14679
pubmed: 25828491
Scheithauer BW et al (2000) Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery 47:723–729. https://doi.org/10.1097/00006123-200009000-00039 . ; discussion 729–730
doi: 10.1097/00006123-200009000-00039
pubmed: 10981760
Cho HY et al (2010) Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf) 72:648–653. https://doi.org/10.1111/j.1365-2265.2009.03673.x
doi: 10.1111/j.1365-2265.2009.03673.x
pubmed: 19650787
Oka H et al (1996) Pituitary choristoma composed of corticotrophs and adrenocortical cells in the sella turcica. Virchows Arch 427:613–617
doi: 10.1007/BF00202893
pubmed: 8605573
Coire CI et al (1998) A composite silent corticotroph pituitary adenoma with interspersed adrenocortical cells: case report. Neurosurgery 42:650–654. https://doi.org/10.1097/00006123-199803000-00039
doi: 10.1097/00006123-199803000-00039
pubmed: 9527001
Guzel A et al (2008) Pituitary carcinoma presenting with multiple metastases: case report. J Child Neurol 23:1467–1471. https://doi.org/10.1177/0883073808319078
doi: 10.1177/0883073808319078
pubmed: 19073854
Tysome J, Gnanalingham KK, Chopra I, Mendoza N (2004) Intradural metastatic spinal cord compression from ACTH-secreting pituitary carcinoma. Acta Neurochir (Wien) 146:1251–1254. https://doi.org/10.1007/s00701-004-0350-0
doi: 10.1007/s00701-004-0350-0
pubmed: 15349756
Graf CJ, Blinderman EE, Terplan KL (1962) Pituitary carcinoma in a child with distant metastases. J Neurosurg 19:254–259. https://doi.org/10.3171/jns.1962.19.3.0254
doi: 10.3171/jns.1962.19.3.0254
pubmed: 13900975
Balili I, Sullivan S, McKeever P, Barkan A (2014) Pituitary carcinoma with endolymphatic sac metastasis. Pituitary 17:210–213. https://doi.org/10.1007/s11102-013-0489-x
doi: 10.1007/s11102-013-0489-x
pubmed: 23645293
Vroonen L et al (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651–662. https://doi.org/10.1530/EJE-12-0236
doi: 10.1530/EJE-12-0236
pubmed: 22918301
AbdelBaki MS et al (2017) Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. J Neurooncol 135:213–215. https://doi.org/10.1007/s11060-017-2554-1
doi: 10.1007/s11060-017-2554-1
pubmed: 28667593
Kaiser FE, Orth DN, Mukai K, Oppenheimer JH (1983) A pituitary parasellar tumor with extracranial metastases and high, partially suppressible levels of adrenocorticotropin and related peptides. J Clin Endocrinol Metab 57:649–653. https://doi.org/10.1210/jcem-57-3-649
doi: 10.1210/jcem-57-3-649
pubmed: 6308034
Lormeau B, Miossec P, Sibony M, Valensi P, Attali JR (1997) Adrenocorticotropin-producing pituitary carcinoma with liver metastasis. J Endocrinol Invest 20:230–236. https://doi.org/10.1007/BF03346909
doi: 10.1007/BF03346909
pubmed: 9211132
Iacovazzo D, Hernandez-Ramirez LC, Korbonits M (2017) Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening. Expert Rev Endocrinol Metab 12:143–153. https://doi.org/10.1080/17446651.2017.1306439
doi: 10.1080/17446651.2017.1306439
pubmed: 30063429
Cuny T et al (2013) Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. Eur J Endocrinol 168:533–541. https://doi.org/10.1530/EJE-12-0763
doi: 10.1530/EJE-12-0763
pubmed: 23321498
Chandrasekharappa SC et al (1997) Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404–407. https://doi.org/10.1126/science.276.5311.404
doi: 10.1126/science.276.5311.404
pubmed: 9103196
Occhi G et al (2013) A novel mutation in the upstream open reading frame of the CDKN1B gene causes a MEN4 phenotype. PLoS Genet 9:e1003350. https://doi.org/10.1371/journal.pgen.1003350
doi: 10.1371/journal.pgen.1003350
pubmed: 23555276
pmcid: 3605397
Verges B et al (2002) Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 87:457–465. https://doi.org/10.1210/jcem.87.2.8145
doi: 10.1210/jcem.87.2.8145
pubmed: 11836268
Trouillas J et al (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32:534–543. https://doi.org/10.1097/PAS.0b013e31815ade45
doi: 10.1097/PAS.0b013e31815ade45
pubmed: 18300794
Giusti F et al (2017) Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine 58:349–359. https://doi.org/10.1007/s12020-017-1234-4
doi: 10.1007/s12020-017-1234-4
pubmed: 28132167
Delemer B (2012) MEN1 and pituitary adenomas. Ann Endocrinol (Paris) 73:59–61. https://doi.org/10.1016/j.ando.2012.03.038
doi: 10.1016/j.ando.2012.03.038
pubmed: 22542456
Hernández-Ramírez L, Faucz CF, Lodish FR, Pankratz M, Chittiboina N, Lane P, Kay J, Mills D, Stratakis J (2019) Non-syndromic Cushing’s Disease due to CDKN1B mutations: novel mutations and phenotypic features in a large Pediatric Cohort. J Endocr Soc 3:OR24–26
doi: 10.1210/js.2019-OR24-6
pmcid: 6554810
de Laat JM et al (2015) Long-term natural course of Pituitary Tumors in patients with MEN1: results from the DutchMEN1 Study Group (DMSG). J Clin Endocrinol Metab 100:3288–3296. https://doi.org/10.1210/JC.2015-2015
doi: 10.1210/JC.2015-2015
pubmed: 26126205
Subasinghe CJ, Somasundaram N, Sivatharshya P, Ranasinghe LD, Korbonits M (2018) Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome. Case Rep Endocrinol 2875074, doi: https://doi.org/10.1155/2018/2875074 (2018)
Gan HW et al (2015) Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1. Int J Pediatr Endocrinol 15, doi: https://doi.org/10.1186/s13633-015-0011-5 (2015)
Kontogeorgos G, Kapranos N, Tzavara I, Thalassinos N, Rologis D (2001) Monosomy of chromosome 11 in pituitary adenoma in a patient with familial multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf) 54:117–120. https://doi.org/10.1046/j.1365-2265.2001.01031.x
doi: 10.1046/j.1365-2265.2001.01031.x
pubmed: 11167934
Vannucci L et al (2018) MEN1 in children and adolescents: data from patients of a regional referral center for hereditary endocrine tumors. Endocrine 59:438–448. https://doi.org/10.1007/s12020-017-1322-5
doi: 10.1007/s12020-017-1322-5
pubmed: 28530019
Vierimaa O et al (2006) Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228–1230. https://doi.org/10.1126/science.1126100
doi: 10.1126/science.1126100
pubmed: 16728643
Daly AF et al (2007) Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92:1891–1896. https://doi.org/10.1210/jc.2006-2513
doi: 10.1210/jc.2006-2513
pubmed: 17244780
Schofl C et al (2014) Frequency of AIP gene mutations in young patients with acromegaly: a registry-based study. J Clin Endocrinol Metab 99:E2789–2793. https://doi.org/10.1210/jc.2014-2094
doi: 10.1210/jc.2014-2094
pubmed: 25093619
Georgitsi M et al (2008) Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin Endocrinol (Oxf) 69:621–627. https://doi.org/10.1111/j.1365-2265.2008.03266.x
doi: 10.1111/j.1365-2265.2008.03266.x
pubmed: 18410548
Daly AF et al (2010) Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 95:E373–383. https://doi.org/10.1210/jc.2009-2556
doi: 10.1210/jc.2009-2556
pubmed: 20685857
Caimari F et al (2018) Risk category system to identify pituitary adenoma patients with AIP mutations. J Med Genet 55:254–260. https://doi.org/10.1136/jmedgenet-2017-104957
doi: 10.1136/jmedgenet-2017-104957
pubmed: 29440248
Naves LA et al (2010) Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. Arq Bras Endocrinol Metabol 54:761–767
doi: 10.1590/S0004-27302010000800017
pubmed: 21340166
Joshi K, Daly AF, Beckers A, Zacharin M (2018) Resistant paediatric somatotropinomas due to AIP mutations: role of Pegvisomant. Horm Res Paediatr 90:196–202. https://doi.org/10.1159/000488856
doi: 10.1159/000488856
pubmed: 29953972
Trivellin G et al (2014) Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med 371:2363–2374. https://doi.org/10.1056/NEJMoa1408028
doi: 10.1056/NEJMoa1408028
pubmed: 25470569
pmcid: 4291174
Daly AF et al (2016) Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. Endocr Relat Cancer 23:221–233. https://doi.org/10.1530/ERC-16-0082
doi: 10.1530/ERC-16-0082
pubmed: 26935837
pmcid: 4877443
Beckers A et al (2015) X-linked acrogigantism syndrome: clinical profile and therapeutic responses. Endocr Relat Cancer 22:353–367. https://doi.org/10.1530/ERC-15-0038
doi: 10.1530/ERC-15-0038
pubmed: 25712922
pmcid: 4433400
Naves LA et al (2016) Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. Endocrine 51:236–244. https://doi.org/10.1007/s12020-015-0804-6
doi: 10.1007/s12020-015-0804-6
pubmed: 26607152
Reincke M et al (2015) Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet 47:31–38. https://doi.org/10.1038/ng.3166
doi: 10.1038/ng.3166
pubmed: 25485838
Ma ZY et al (2015) Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res 25:306–317. https://doi.org/10.1038/cr.2015.20
doi: 10.1038/cr.2015.20
pubmed: 25675982
pmcid: 4349249
Faucz FR et al (2017) Somatic USP8 gene mutations are a Common cause of Pediatric Cushing Disease. J Clin Endocrinol Metab 102:2836–2843. https://doi.org/10.1210/jc.2017-00161
doi: 10.1210/jc.2017-00161
pubmed: 28505279
pmcid: 5546857
Albani A et al (2018) The USP8 mutational status may predict long-term remission in patients with Cushing’s disease. Clin Endocrinol (Oxf). https://doi.org/10.1111/cen.13802
doi: 10.1111/cen.13802
pubmed: 29957855
Cohen M et al (2019) Germline USP8 mutation associated with pediatric cushing disease and other clinical features: a new syndrome. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2019-00697
doi: 10.1210/jc.2019-00697
pubmed: 31390015
pmcid: 7075107
de Kock L et al (2014) Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations. Acta Neuropathol 128:111–122. https://doi.org/10.1007/s00401-014-1285-z
doi: 10.1007/s00401-014-1285-z
pubmed: 24839956
pmcid: 4129448
Tatsi C, Stratakis CA (2018) Neonatal cushing syndrome: a rare but potentially devastating disease. Clin Perinatol 45:103–118. https://doi.org/10.1016/j.clp.2017.10.002
doi: 10.1016/j.clp.2017.10.002
pubmed: 29406000
Foulkes WD, Priest JR, Duchaine TF (2014) DICER1: mutations, microRNAs and mechanisms. Nat Rev Cancer 14:662–672. https://doi.org/10.1038/nrc3802
doi: 10.1038/nrc3802
pubmed: 25176334
Tatsi C et al (2019) Large genomic aberrations in Corticotropinomas are Associated with Greater aggressiveness. J Clin Endocrinol Metab 104:1792–1801. https://doi.org/10.1210/jc.2018-02164
doi: 10.1210/jc.2018-02164
pubmed: 30597087
Bi WL et al (2017) Landscape of genomic alterations in Pituitary Adenomas. Clin Cancer Res 23:1841–1851. https://doi.org/10.1158/1078-0432.CCR-16-0790
doi: 10.1158/1078-0432.CCR-16-0790
pubmed: 27707790